Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
BCR-ABL STAMP inhibitor
Asciminib
Scemblix · ASC
Allosteric (STAMP) BCR-ABL1 inhibitor binding the myristoyl pocket — its renal-relevant signals are hypertension and pancreatitis, not a direct nephropathy.
MildAllosteric TKI era · approved 2021
Chronic-phase chronic myeloid leukemia after >=2 prior tyrosine kinase inhibitorsChronic-phase CML with the T315I mutation
Signature kidney injury
Hypertension
Hypertension and pancreatitis (with amylase/lipase elevations) are recognized toxicities; thrombocytopenia/neutropenia are common. Asciminib has a notably cleaner profile than prior TKIs, and direct nephrotoxicity is not a defined signal — renal effects are largely hypertension-mediated.
Source: Rea et al., Blood 2021 (ASCEMBL); Hughes et al., N Engl J Med 2019
Mechanism of kidney injury
Asciminib's renal relevance is principally vascular: treatment-emergent hypertension (a class effect of BCR-ABL inhibitors via endothelial/vascular signaling) raises systemic and glomerular pressure and, if uncontrolled and chronic, can contribute to hypertensive kidney injury. Pancreatitis can cause volume shifts and prerenal physiology in severe cases. There is no characteristic direct tubular or glomerular lesion; cardiovascular/vascular occlusive events are tracked as a class concern.
Clinical presentation
New or worsening hypertension; epigastric pain with elevated lipase/amylase in pancreatitis. Renally, a hypertension-associated creatinine trend rather than an acute structural picture; severe pancreatitis can produce dehydration and prerenal AKI.
Onset
Hypertension can emerge across treatment; pancreatitis often early.
Reversibility
Reversible
Anticancer mechanism
First-in-class allosteric BCR-ABL1 inhibitor that binds the myristoyl pocket (Specifically Targeting the ABL Myristoyl Pocket, STAMP) rather than the ATP site, locking the kinase inactive. This circumvents many ATP-site resistance mutations (including T315I at higher dose) in chronic myeloid leukemia.
Management
Control hypertension with standard antihypertensives and continue cardiovascular risk reduction; this protects the kidney from pressure-mediated injury. Manage pancreatitis supportively (IV fluids, holding drug) and treat any resultant prerenal AKI with volume repletion. Dose-interrupt/reduce for significant toxicity; renal effects are generally reversible with control of BP and pancreatitis.
Risk factors
- Pre-existing hypertension or cardiovascular disease
- Prior TKI vascular toxicity
- History of pancreatitis or hypertriglyceridemia
- Baseline CKD
Prevention
- Baseline and periodic blood-pressure monitoring with proactive treatment
- Monitor lipase/amylase, especially early; assess pancreatitis risk factors
- Cardiovascular risk-factor optimization
- Dose interruption for grade 3+ hypertension or pancreatitis per label
Note · The renal link is indirect — chiefly hypertension-mediated, with pancreatitis-related volume shifts in severe cases; there is no characteristic direct asciminib nephropathy.
Clinical depth
Renal dose adjustment
No dose adjustment required for renal impairment in labeling (renal clearance is minor); use general caution in advanced CKD. Hepatic metabolism predominates.
Dialyzability & ESKD dosing
Highly protein-bound; not expected to be dialyzable. No specific ESKD dosing required given minimal renal clearance.
Differential diagnosis
Distinguish hypertension-mediated renal effects from other TKI vascular toxicity and essential hypertension; separate pancreatitis-driven prerenal AKI from intrinsic causes. The absence of a tubular/glomerular lesion is reassuring.
Monitoring
- Blood pressure at baseline and regularly
- Serum lipase/amylase periodically and with abdominal symptoms
- CBC (cytopenias) per schedule
- Serum creatinine periodically in patients with hypertension/CKD
Key trials & series
- ASCEMBL (Rea, Blood 2021) — registrational RCT vs bosutinib quantifying hypertension/pancreatitis
- Hughes et al. (NEJM 2019) — first-in-human dose-escalation including T315I activity and toxicity
Clinical pearls
- Asciminib's allosteric (myristoyl-pocket/STAMP) mechanism gives a cleaner off-target profile than ATP-site TKIs.
- Its renal-relevant signals are hypertension and pancreatitis — manage BP to protect the kidney.
- Minimal renal clearance means no renal dose adjustment is needed.
- Lipase elevations are often asymptomatic; correlate with symptoms before stopping.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
HypertensionElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of bcr-abl stamp inhibitors.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Vascular occlusion (ponatinib), fluid retention
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Pleural effusions (dasatinib), PAH
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- QT, heart failure
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkAsciminib, a specifically targeting the ABL myristoyl pocket inhibitor, vs bosutinib in chronic-phase chronic myeloid leukemia after >=2 prior tyrosine kinase inhibitors (ASCEMBL).Rea D et al. · Blood 2021 · PMID 34407542Registrational RCT defining efficacy and the hypertension/pancreatitis safety profile.PMIDAsciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.Hughes TP et al. · N Engl J Med 2019 · PMID 31826340First-in-human dose-escalation establishing the allosteric mechanism and early toxicity.PMIDAsciminib monotherapy in patients with chronic-phase chronic myeloid leukemia: long-term follow-up.Hochhaus A et al. · Leukemia 2023 · PMID 36717654Longer-term safety confirming the hypertension/cytopenia profile.PMIDAsciminib in Newly Diagnosed Chronic Myeloid Leukemia (ASC4FIRST).Hochhaus A et al. · N Engl J Med 2024 · PMID 38820078Frontline RCT extending the safety dataset including vascular/metabolic events.PMIDAsciminib: the first STAMP inhibitor in chronic myeloid leukemia.Assanto GM et al. · Ther Adv Hematol 2022 · PMID 36305542Mechanistic review of the myristoyl-pocket allosteric inhibition.PMIDAdverse event profile of asciminib: a real-world pharmacovigilance analysis.Liu Y et al. · Front Pharmacol 2024 · PMID 39102794FAERS disproportionality analysis characterizing real-world toxicity signals.
Related agents
Other agents sharing the same signature kidney injury.